The price of Ruxolitinib tablets in China

Ruxolitinib is a Janus-activated kinase inhibitor (JAK) that selectively inhibits JAK1 and JAK2 protein kinases. It is an oral drug approved by the FDA to treat blood and bone marrow cancers. It works by blocking a protein that causes cancer cells to grow and multiply, which helps slow or stop the spread of cancer cells. It may also be used to treat conditions that develop after stem cell or bone marrow transplants (graft-versus-host disease). Common brand names of ruxolitinib tablets include Jakafi and Jakavi. The original drug is developed by Incyte, Novartis and other companies.

Ruxolitinib tabletsThe original drug has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications, including limited to intermediate-risk or high-risk primary myelofibrosis(PMF), For patients with myelofibrosis secondary to polycythemia vera (PPV-MF) or myelofibrosis secondary to essential thrombocythemia (PET-MF), the price of 5mg*60 tablets per box may be around RMB 3,000.

The Turkish version of ruxolitinib tablets sold overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.